• Skip to main content
  • Skip to footer

EydisBio

  • About Us
  • Technology
    • Pipeline
  • Therapeutic indications
    • Rheumatoid Arthritis
    • Chronic Pain
    • COVID-19 ARDS
  • Our Team
  • Resources
    • Publications & Press Releases
    • FCOI
    • Partners & Funders
  • Contact

Rheumatoid Arthritis

Applying our technology to combat drug non-response or resistance faced by rheumatoid arthritis patients

Rheumatoid Arthritis

The challenges being faced by RA patients

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which hyperactivated immune cells induce maladaptive persistent inflammation in the joints, leading to synovial inflammation and bone remodeling. In the US, RA currently affects roughly 1% of the population and carries a total annual societal cost burden of approximately $39.2 billion. In RA, sustained elevations of pro-inflammatory cytokines elicit chronic tissue damage and pain, which ultimately leads to loss of mobility and significant impairment of the patient’s lifestyle.

Development and approval of anti-tumor necrosis factor (anti-TNF) biological therapies (e.g., Humira, Enbrel, and Remicade) has transformed treatment options for patients with moderate to severe RA. However, over 40% of patients taking anti-TNF biologics either fail to respond to initial treatment or lose response over time, leading to the need for experimental cycling through other anti-TNFs or JAK inhibitors to manage disease. However, due to cytokine oversuppression, all of these therapies suffer from serious safety issues including risks of infections, malignancies, cardiotoxicities and blood clots. Thus, there is a clear need for a novel, potent and highly selective, orally bioavailable TAK1 inhibitor that affords RA patients the benefits of anti-TNF therapy without the shortcomings of biologics, coupled with a superior safety profile through restoration of self-tolerance versus immune oversuppression.

Over 40% of patients fail to
respond, or lose response over time, to conventional
antibody-based therapies

This result is due mainly to the formation of anti-drug
antibodies

Solution: Development of
orally bioavailable small
molecule inhibitors
of TAK1

How EYD-001 can be applied

Working to combat drug resistance and non-response among RA patients

Unlike biologic-based therapies, small molecule drugs are not immunogenic and thus do not elicit an immunological response to the drugs themselves. This avoidance allows for a more targeted treatment regimen with a larger therapeutic window. Additionally, dosing paradigms can be more easily adjusted within the therapeutic range for maximum efficacy. As a result, as opposed to anti-TNF injections or infusions, EYD-001's target product profile aims to provide patients with highly effective once-a-day oral dosing coupled with a superior safety profile.

Eyd 001 Efficacy Vs Enbrel

Learn more

Benefits of Our
Application

Orally bioavailable small molecule therapeutic, novel MOA, highly potent and exquisitely selective anti-TNF

Selective targeting of
TNF signaling provides for a larger therapeutic window, superior efficacy, improved safety (i.e., immune/TNF dampening vs oversuppression)

 

Customized dosing
regimens which are more easily adjustable to fit patients' needs

Additional information and resources

Our Technology

First selective orally bioavailable inhibitors of TAK1 for the treatment of RA

Discover our technology

Our Company

EydisBio is a small biotech located in Durham, North Carolina. Originally created as a spinout of Duke University, EydisBio has gone on to become a leader for the development of selective and potent small molecule inhibitors of disease relevant kinases.

Learn more about us

Our Team

Our team is composed of experienced pharmacologists, chemists, and biologists who leverage their years of industry experience to advance small molecule inhibitors into clinics.

Meet our team

EydisBio

201 W. Main Street, Suite #317
Durham, NC 27701

Footer Office Img

Get Directions

"*" indicates required fields

GDPR Consent*
This field is for validation purposes and should be left unchanged.

Footer Logo

201 W Main Street, Suite #317, Durham, NC, 27701
Privacy Policy | Web Accessibility. Design by TinyFrog Technologies

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits.
By clicking “Accept”, you consent to the use of ALL the cookies. AcceptReject
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT